Clinical trial
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With…
NCT00436241 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00436241 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer. |
| Official title | A Open Label Study of the Effect of First-line Therapy With Xeloda in Combination With Oxaliplatin on Overall Response Rate in Patients With Locally Advanced and/or Metastatic Gastric Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | Oxaliplatin, capecitabine [Xeloda] |
| Enrollment | 45 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Feb 19, 2007 |
| Last update posted | Nov 2, 2016 |
| Countries | Taiwan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: